Key facts
- This page summarizes Joseph C. Papa's Form 4 filing for Emergent BioSolutions Inc. (EBS).
- 2 reported transactions and 2 derivative rows are listed below.
- Accepted by SEC: 12 Mar 2025, 18:12.
Joseph C. Papa - 12 Mar 2025 Form 4 Insider Report for Emergent BioSolutions Inc. (EBS)
- Reporting relationship
- President and CEO, Director
- Issuer ticker
- EBS
- Reported as of
- 12 Mar 2025
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 12 Mar 2025, 18:12:58 UTC
- Prior SEC filing
- 10 Mar 2025
- Next SEC filing
- 15 May 2025
- Source filing
- View source filing
- Reporting owner signature
- /s/ Richard S. Lindahl, Attorney-in-fact
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Joseph C. Papa filed Form 4 for Emergent BioSolutions Inc. (EBS) on 12 Mar 2025.
Change
- Previous filing in this sequence was filed on 10 Mar 2025.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
EBS
transaction
Derivative
Employee Stock Options (Right to Buy)
Award
- Transaction value
- $0
- Shares
- +250,000
- Change %
- +24%
- Price
- $0.000000
- Shares after
- 1,282,500
- Date
- 12 Mar 2025
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 250,000
- Exercise price
- $2.33
- Footnotes
- F1
EBS
transaction
Derivative
Employee Stock Options (Right to Buy)
Award
- Transaction value
- $0
- Shares
- +250,000
- Change %
- +19%
- Price
- $0.000000
- Shares after
- 1,532,500
- Date
- 12 Mar 2025
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 250,000
- Exercise price
- $2.33
- Footnotes
- F1
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 1 footnote
Footnote F1
Consists of an award of performance stock options granted under the company's Inducement Plan. These performance stock options vested in one annual installment on the day prior to the first anniversary of the date of grant based on the achievement of the $5 and $10 stock price performance hurdles as described in Mr. Papa's executive employment agreement dated February 19, 2024 (the "Papa Employment Agreement") and as certified by the company's Compensation Committee on February 12, 2025. Pursuant to the award, there remains 250,000 unvested performance stock options that are subject to a $15 stock price performance hurdle as described in the Papa Employment Agreement. Each performance stock option represents the right of the Reporting Person to receive one share of common stock of Emergent BioSolutions Inc. at the exercise price.